Skip to content

Clinical observation of neoadjuvant interventional therapy combined with concurrent radiotherapy and chemotherapy for advanced cervical cancer

Clinical observation of neoadjuvant interventional therapy combined with concurrent radiotherapy and chemotherapy for advanced cervical cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300067449
Enrollment
Unknown
Registered
2023-01-09
Start date
2023-01-16
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer

Interventions

Test group:Paclitaxel-albumin+carboplatin+radiotherapy

Sponsors

Yiyang Center Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Patients diagnosed as cervical cancer by pathological biopsy; 2) The clinical stage is ? b~? a (FIGO 2018 cervical cancer stage); 3) KPS score = 70; 4) There are measurable primary target lesions by MRI or CT; 5) Expected life = 6 months; 6) Age 18-75; 7) Hematology, liver and kidney functions were basically normal (hematology: absolute neutrophil count = 1500/ul, platelet = 100000/ul, hemoglobin = 9g/dl; renal function: serum creatinine = 1.5 times the upper limit of normal value; liver function: serum total bilirubin = 1.5 times the upper limit of normal value, aspartate aminotransferase = 1.5 times the upper limit of normal value, alanine aminotransferase = 1.5 times the upper limit of normal value, alkaline phosphatase = 1.5 times); 8) The patient signed the consent form for clinical study, interventional therapy, chemotherapy and radiotherapy.

Exclusion criteria

Exclusion criteria: 1) patients who have contraindications of interventional therapy, radiotherapy and chemotherapy, and allergy to albumin paclitaxel, carboplatin and cisplatin; 2) Patients with severe diseases such as gastrointestinal bleeding and perforation; 3) Pregnant and lactating women; 4) patients with a second malignant tumor; 5) Serious liver and kidney diseases, respiratory diseases or chronic diseases such as uncontrollable diabetes and hypertension; 6) Patients with mental disorder; 7) The evaluation criteria of common adverse reactions were>2 grade for severe clinical infections in active stage; 8) Patients who have a history of organ transplantation; 9) Alcohol or drug abuse; 10) No civil capacity or limited civil capacity.

Design outcomes

Primary

MeasureTime frame
PFS;

Secondary

MeasureTime frame
ORR;DCR;OS;QOL;

Countries

China

Contacts

Public ContactLi Xiantao

Yiyang Center Hospital

luolong338_2022@126.com15907371697

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026